A recent Urology digest,
as sent to subscribers

Study Type: Retrospective video-based analysis of prospectively collected registry data (n=100; age-matched subgroup n=66).

Key Question: Does objectively assessed intraoperative surgical performance predict 12-month erectile function after bilateral nerve-sparing RARP?

Key Findings:

• Cases with erectile dysfunction at 12 months had 43% more total errors and 67% more NVB dissection errors than cases with good outcomes (P<0.001); age-matched analysis showed 31–54% differences (P<0.001).
• Step completion and critical errors did not differ between groups; inter-rater reliability of video scoring was high (0.91).
• Demographic and clinical variables did not differ between outcome groups.

Clinical Relevance: Supports structured video-based performance assessment as a basis for surgeon feedback, credentialing and quality assurance in UK robotic prostatectomy programmes.

Limitations: Small sample from seven experienced surgeons with selected preoperatively potent patients; the abstract does not report adjusted effect sizes or confidence intervals, and the outcome threshold and ED definition are not specified.

Study Type: Single-centre retrospective cohort study with propensity score matching (104 matched pairs from 340 open radical cystectomy patients)

Key Question: Do Hautmann and modified Studer orthotopic neobladder configurations differ in urinary diversion-specific complications, perioperative outcomes, or patient-reported outcomes?

Key Findings:

• At median 3 years, composite UD-specific complications (upper tract, anastomotic leak, infection), Clavien-Dindo ≥III complications, short-term mortality, HRQoL and decision regret did not differ significantly.
• Exploratory multivariable analysis linked modified Studer to higher neobladder outlet obstruction (OR 2.99, 95% CI 1.15–8.78) and 90-day readmission (OR 1.87, 95% CI 1.05–3.39).
• Among ISC users, modified Studer scored higher on ISC ease-of-use (β +17.4, 95% CI 1.40–33.5).

Clinical Relevance: Reassures that either configuration is reasonable, though the signal for outlet obstruction with modified Studer may inform configuration choice and counselling in UK centres offering ONB.

Limitations: Single-centre, open-surgery cohort with wide confidence intervals; the outlet obstruction and readmission findings were exploratory and require multicentre validation.

Study Type: Systematic review and meta-analysis

Key Question: Are intracellular ACP1 and ACP3 expression associated with prostate cancer presence, aggressiveness, and survival?

Key Findings:

• Low ACP3 (the gene encoding prostatic acid phosphatase) expression was seen in cancer tissue (OR 0.30, P = 0.006) and associated with higher Gleason grade (OR 0.44, P = 0.031), advanced stage, nodal involvement, and poorer survival.
• ACP1 was more frequently elevated in patients (HR 2.24, P < 0.001) and correlated with high Gleason grade (HR 3.75, P < 0.001), advanced stage, nodal metastasis, and worse survival.
• The ACP1 evidence came from only a limited number of studies and is described as preliminary.

Clinical Relevance: ACP3 and ACP1 may eventually contribute to tissue-based risk stratification, but this remains hypothesis-generating with no immediate change to NHS practice.

Limitations: The ACP1 findings rest on few studies, and the abstract reports no heterogeneity, study numbers, or risk-of-bias assessment, so confidence in the pooled estimates cannot be judged.

Study Type: In vitro experimental study (three complementary bench models using BegoStone phantoms; prototype device).

Key Question: Does StoneSense™ automatic target recognition, integrated into a thulium fibre laser, restrict firing to a defined stone-to-fibre distance, and does this alter ablation efficiency, energy delivery and thermal rise?

Key Findings:

• Laser firing was confined to ~2.3-2.7 mm from the stone, with no significant effect of LED intensity or pulse frequency (10 vs 20 Hz at 1 J).
• In the cuvette model, ATR reduced active laser time (146 vs 179 s) and energy delivered (1.46 vs 1.79 kJ), improved ablation efficiency (1.77 vs 1.42 mg/J) and lowered temperature rise (4.2 vs 5.1°C; P = 0.001), at the cost of modestly longer procedure time.
• In simulated RIRS, ATR increased ablated mass and efficiency (P < 0.05) with longer procedural duration.

Clinical Relevance: ATR could reduce off-target laser emission and thermal load during ureteroscopic lithotripsy, but it is not yet clinically validated and should not influence UK practice until in vivo data emerge.

Limitations: Bench-only testing on phantom stones with a prototype and small sample sizes, with no clinical outcomes (stone-free rate, complications, tissue injury) and a ~1 °C temperature difference of uncertain clinical significance.

Study Type: Systematic review and meta-analysis of observational studies (PROSPERO-registered, PRISMA 2020; ROBINS-I risk of bias).

Key Question: What are the patency, continence and erectile outcomes of urethroplasty for bulbomembranous strictures after endoscopic BPH surgery?

Key Findings:

• Pooled patency 90% (95% CI 85-93%; 9 studies, 417 patients), mostly defined as freedom from re-intervention. Ventral onlay BMG 87%, anastomotic 94%, dorsal onlay BMG 91% (one study only).
• Pooled urinary incontinence 5% (95% CI 3-10%); results consistent after excluding simple prostatectomy cases.
• Erectile data insufficient to pool; two studies reported no significant SHIM deterioration.

Clinical Relevance: Supports urethroplasty as an option with low incontinence risk in this difficult post-BPH population, relevant to counselling and referral to reconstructive centres in the UK.

Limitations: Evidence is non-comparative, retrospective or observational with moderate-to-serious bias, and uses heterogeneous patency and continence definitions, so technique comparisons are not reliable.

Study Type: Narrative technical review with accompanying surgical video (Surgery in Motion); not original research.

Key Question: What are the current open, video-endoscopic (VEIL) and robot-assisted (RAVEIL) techniques for inguinal lymph node dissection in penile cancer, and where does each have a role?

Key Findings:

• Open ILND remains the reference approach, particularly for advanced nodal disease.
• Minimally invasive techniques may reduce wound-related morbidity and can be considered in selected patients with limited nodal disease at experienced centres.
• Across approaches, adherence to anatomical templates, careful patient selection and preservation of lymphatic/vascular structures where oncologically safe are central to limiting morbidity.
• The abstract provides no quantitative outcome data.

Clinical Relevance: Provides practical technical guidance relevant to UK penile cancer centres considering MI-ILND, supporting training and standardisation within the national supra-regional network.

Limitations: Educational overview without reported outcome data; long-term oncological efficacy of MI approaches and emerging technologies remains unproven.

Study Type: Prospective case-cohort study (EPIC) with partial external replication (ARIC), supported by Mendelian randomization and exome gene-burden analyses.

Key Question: Which circulating plasma proteins, measured at baseline, are associated with future risk of overall and aggressive prostate cancer?

Key Findings:

• Among 982 incident cases and 1573 subcohort participants, ACP3, FLT4 and KLK3 were associated with overall PCa (HR per 1 SD: 1.20, 1.26 and 2.28 respectively). Seven proteins were associated with aggressive PCa (n=290), with ANKRD1 consistent across disease subtypes.
• Twelve proteins, including ANXA2, GZMK and OSCAR, were associated with PCa diagnosed >15 years after blood draw. ACP3, ANXA2, APOC2 and KLK3 replicated in ARIC.
• Circulating products of driver genes (ERBB3, KRAS, NRAS) were associated with future aggressive disease. Four proteins had MR support and eight had rare-variant burden support.

Clinical Relevance: Findings are hypothesis-generating for future risk-stratification biomarkers beyond PSA (KLK3), which may inform UK debate on targeted early detection, but have no current clinical application.

Limitations: External replication was incomplete (only four proteins replicated), and end-point availability differed between cohorts.

Study Type: Narrative review with secondary analysis of GLOBOCAN 2024 registry data and projections to 2050.

Key Question: How do prostate cancer incidence, mortality, risk factors and prevention opportunities vary globally, and how will the burden change by 2050?

Key Findings:

• An estimated 1.55 million new cases (incidence ASR 29/100,000) and 420,000 deaths (7.5/100,000) occurred in 2024; incidence was highest in Northern America (ASR 81) and lowest in South-Central Asia (7.2), reflecting PSA screening patterns.
• Projections assuming unchanged 2024 rates suggest 2.88 million cases (+86%) and 924,000 deaths (+120%) by 2050, with the largest relative rise in Africa (+156%).
• No nutrient or supplement reduces incidence; smoking and obesity are linked to cancer-specific mortality, while exercise and Mediterranean/plant-based diets are associated with lower progression risk. African-ancestry mortality gaps narrow in equal-access systems.

Clinical Relevance: Supports risk-stratified, genetics-informed discussions of screening and lifestyle counselling, and highlights access to care as a driver of ethnic disparities relevant to NHS practice.

Limitations: Projections reflect demographic change only (static age-specific rates), and the risk factor review is narrative with no stated systematic methodology.